

## *Supplementary Material*

# Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis

Li Song<sup>1</sup>, Yan Liu<sup>1</sup>, Zhixin Chen<sup>2</sup>, Zeyan Li<sup>3</sup>, Shiqin Zhu<sup>3</sup>, Yingjie Zhao<sup>4,5</sup>, Huihui Li<sup>1\*</sup>

\* **Correspondence:** Huihui Li: hhli\_qilu@email.sdu.edu.cn

## 1 Subgroup analysis

We conducted separate subgroup analyses to explore whether different treatment regimens, treatment lines, ages, and adverse reactions were associated with the risk of stroke-related adverse reactions. Among them, the incidence of stroke-related adverse events of bevacizumab was 0.01% (95% CI: 0.00-0.01,  $p < 0.01$ ) in newly diagnosed patients (Figure S1A) and 0.01% (95% CI: 0.01-0.02,  $p = 0.55$ ) in patients with recurrent ovarian cancer (Figure S1B). In addition, subgroup analyses showed that the incidence of stroke-related adverse events in the carboplatin + paclitaxel + bevacizumab group was 0.01% (95% CI: 0.00-0.01,  $p < 0.01$ ; Figure S2). The incidence of stroke-related adverse events was 0.01% (95% CI: 0.00-0.01,  $p = 0.08$ ) in patients aged  $< 60$  years (Figure S3A) and 0.01% (95% CI: 0.00-0.01,  $p < 0.01$ ) in patients aged  $\geq 60$  years (Figure S3B). The incidence of stroke caused by cerebral ischemia (Figure S4A) and cerebral bleeding (Figure S4B) was 0.01% (95% CI: 0.01-0.02,  $p = 0.27$ ) and 0.01% (95% CI: 0.00-0.01,  $p < 0.01$ ), respectively.

## 2 Supplementary Figures



**Supplementary Figure 1.** Subgroup analysis. (A) Forest plots of the incidence of stroke related adverse reactions in ovarian cancer patients with primary bevacizumab-treat. (B) Forest plots of the incidence of stroke related adverse reactions in ovarian cancer patients in ROC bevacizumab-treat.

**Supplementary Figure 2.** Subgroup analysis. Forest plot of the incidence of stroke related adverse reactions in paclitaxel + platinum plus bevacizumab-treated ovarian cancer patients.

**Supplementary Figure 3.** Subgroup analysis. (A) Forest plots of the incidence of stroke related adverse reactions in bevacizumab-treated ovarian cancer patients with age  $< 60$ . (B) Forest plots of the

incidence of stroke related adverse reactions in bevacizumab-treated ovarian cancer patients with age  $\geq 60$ .

**Supplementary Figure 4.** Subgroup analysis. (A) Forest plots of the incidence of CNS ischemia in bevacizumab-treated ovarian cancer patients.(B) Forest plots of the incidence of CNS bleeding in bevacizumab-treated ovarian cancer patients.